Dare Bioscience 提交8-K披露最新企業簡報 積極與投資者溝通

false
 0001401914
 
 
 
 
 
 
 
 0001401914
 
 
 2026-07-13
 2026-07-13
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

 

Pursuant
to Section 13 or 15(d)

of
the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): July 13,
2026

 Dare Bioscience, Inc.

DARÉ
BIOSCIENCE, INC.

(Exact
name of registrant as specified in its charter)

 

 
 Delaware
  
 001-36395
  
 20-4139823

 
 (State
 or other jurisdiction

 of
 incorporation)

  
 (Commission

 File
 Number)

  
 (I.R.S.
 Employer

 Identification
 No.)

 
 

3655
Nobel Drive, Suite
260

San
Diego, CA
92122

(Address
of Principal Executive Offices and Zip Code)

 

Registrant’s
telephone number, including area code: (858)
926-7655

 

Not
Applicable

(Former
name or former address, if changed since last report.)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common
 stock
  
 DARE
  
 Nasdaq
 Capital Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
7.01 Regulation FD Disclosure.

 

Furnished
as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the
“Company”) dated July 13, 2026, which is incorporated herein by reference. The Company intends to use the presentation and
its contents in various meetings with securities market participants and others, commencing on July 13, 2026.

 

The
Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com),
on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained
in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated
by reference into this report.

 

The
information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation
by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

 

Item
9.01 Financial Statements and Exhibits.

 

(d)
Exhibits.

 

 
 Exhibit
 No.
  
 Description

 
 99.1
  
 Daré
 Bioscience corporate presentation, dated July 13, 2026

 
 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

 
 

 -2-

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
 DARÉ
 BIOSCIENCE, INC.

 
  
  

 
 Dated:
 July 13, 2026
 By:
 /s/
 Sabrina Martucci Johnson

 
  
 Name:
 Sabrina
 Martucci Johnson

 
  
 Title:
 President
 and Chief Executive Officer

 
 

 -3-